Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Capital Employed: 2014-2025

Historic Return on Capital Employed for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to -0.88%.

  • Coherus Oncology's Return on Capital Employed fell 12.00% to -0.88% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.88%, marking a year-over-year decrease of 12.00%. This contributed to the annual value of -0.44% for FY2024, which is 47.00% up from last year.
  • Per Coherus Oncology's latest filing, its Return on Capital Employed stood at -0.88% for Q3 2025, which was down 30.45% from -0.67% recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Return on Capital Employed peaked at -0.10% during Q1 2021, and registered a low of -1.28% during Q1 2024.
  • Its 3-year average for Return on Capital Employed is -0.78%, with a median of -0.76% in 2024.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first plummeted by 78bps in 2021, then soared by 71bps in 2025.
  • Over the past 5 years, Coherus Oncology's Return on Capital Employed (Quarterly) stood at -0.48% in 2021, then fell by 20bps to -0.68% in 2022, then decreased by 6bps to -0.74% in 2023, then climbed by 16bps to -0.58% in 2024, then declined by 12bps to -0.88% in 2025.
  • Its Return on Capital Employed stands at -0.88% for Q3 2025, versus -0.67% for Q2 2025 and -0.58% for Q1 2025.